The contract development and manufacturing organization (CDMO) announced the establishment of the new facility at BIO International, in San Francisco this week.
The new facility will include space for Phase III and commercial production of viral vector-based and cell-based advanced therapies and is expected to be qualified and operational by the second quarter of 2017.
As Outsourcing-Pharma.com previously reported, the company recently merged with Flordia Biologix – adding capabilities in process development and phase I/II manufacturing.
“We are now entering the year of personalized medicine,” Brammer Bio President and CEO Mark Bamforth said at a press event at BIO International on Tuesday. “What has been an idea and a plan in people’s minds for several decades is now coming to fruition.”
Bamfroth added that the company will eventually employ up to 200 people in the new facility with a total of $50m invested, “to provide these therapies for our clients to they can bring them to patients around the world.”
Massachusetts’s Secretary of Economic Development, Jay Ash, also spoke at the event, thanking Brammer for its commitment to the state.
“A couple of years ago when Massachusetts was talking about being number one in life sciences, that meant research and development … but we’re now having conversation after conversation about manufacturing,” he said.